You are here

Article Text

Article menu

Download PDFPDF

Perspective
Clinical diagnosis and treatment of “atypical” HELLP syndrome
  1. Ying-dong He and
  2. Hui-xia Yang*
  1. Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, PR China
  1. ↵*Corresponding author. yanghuixia{at}bjmu.edu.cn

Abstract

HELLP syndrome is regarded as one of the most serious manifestations of preeclampsia, but approximately 15% of patients with HELLP syndrome have no clinical manifestations of preeclampsia; furthermore, although most cases of HELLP syndrome occur after 34 weeks, some cases occur at a much earlier gestational stage, even before 20 weeks of gestation, the underlying pathogenesis of “atypical” HELLP syndrome with very early onset or the basis of non-preeclampsia manifestations should be more actively explored. Obstetricians should carefully identify the potential etiology of “atypical” HELLP syndrome in order to provide a reasonable treatment and improve maternal and fetal prognosis.

  • HELLP syndrome
  • Atypical
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.gocm.2022.08.001

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In 1954, Pritchard JA1 first described three patients with intravascular hemolysis, thrombocytopenia and hematologic abnormalities on the basis of severe preeclampsia, in 1982, Weinstein2 put together the data for 29 patients with similar clinical features that result in the famous article “Syndrome of hemolysis，elevated liver enzymes， and low platelet count: A severe consequence of hypertension in pregnancy”, due to the potential fatality of the disease, he developed a name for the disease with “warning” significance: hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome.3 Today, obstetricians have a better understanding of HELLP syndrome, and most cases of HELLP syndrome that are based on preeclampsia are easy to address, but the diagnosis of HELLP syndrome without preeclampsia manifestations is still difficult. For HELLP syndrome that occurs in the earlier stages of pregnancy, the differential diagnosis of this “atypical” syndrome is still difficult. How to deal with cases of “atypical” HELLP syndrome is a challenge for obstetricians. In this paper, we analyze the current diagnostic criteria of HELLP syndrome. The existing clinical treatment strategies for HELLP syndrome are explored in combination with the pathogenesis, and the differential diagnosis of atypical HELLP syndrome is introduced to provide a reference for obstetric clinical practice.

    1 Diagnostic criteria for HELLP syndrome

    Although Weinstein proposed the nomenclature of HELLP syndrome, the diagnostic criteria for HELLP syndrome that are used for clinical diagnosis and research are not actually uniform. Both the relatively strict Tennessee criteria4 and Mississippi grades5 that define disease severity situation exist. In 2004, Sibai6 proposed controversial problems in the diagnostic criteria for HELLP syndrome. The differences in these diagnostic criteria arise from the large range of variations in the experimental diagnostic criteria themselves on the one hand and from the knowledge of physicians or researchers about the development process of HELLP syndrome on the other hand. Based on the guidelines for the diagnosis and treatment of hypertensive disorders of pregnancy in China,7 the diagnostic criteria for HELLP syndrome used include the following: microvascular hemolysis (H), including elevated lactate dehydrogenase (LDH) levels, fragmented red blood cells and spherocytes in peripheral blood smears, bilirubin levels ≥20.5 μmol/L, and mildly decreased hemoglobin levels; elevated transaminase levels (EL), including alanine aminotransferase (ALT) levels ≥40 U/L or aspartate aminotransferase (AST) levels ≥70 U/L; and decreased platelet counts (LP), including platelet counts <100 ​× ​109/L.

    As shown through the above diagnostic criteria, preeclampsia-related clinical manifestations are not necessary for the diagnosis of HELLP syndrome; moreover, the diagnostic criteria of partial HELLP syndrome actually overlap with those of severe preeclampsia (SPE). Over the years, it has been traditionally believed that HELLP syndrome is closely associated with SPE, and approximately 2%∼12%8 of patients with preeclampsia develop HELLP syndrome; however, HELLP syndrome has special characteristics independent of preeclampsia: its diagnostic criteria include neither the time limit of 20 weeks of gestation that is required for the diagnosis of preeclampsia nor the inclusion of the symptomatology-related manifestations of preeclampsia. In clinical work, approximately 15% of patients with HELLP syndrome have no clinical manifestations of preeclampsia, such as hypertension or proteinuria, which requires us to break the concept that there is an inevitable association between preeclampsia and HELLP syndrome, and on the basis of recognizing that HELLP syndrome is a serious clinical manifestation of hypertensive disorders of pregnancy, some cases of HELLP syndrome with “atypical” clinical manifestations should also be fully recognized and considered.9,10

    2 Debate on the current diagnosis and management of HELLP syndrome

    As mentioned above, in the current clinical work, HELLP syndrome is regarded as one of the most serious manifestations of hypertensive disorders of pregnancy in most cases, so the treatment of such patients is similar to that of patients with SPE and involves maternal supportive treatment, fetal monitoring, antenatal corticosteroid therapy for fetal lung maturation, magnesium sulfate therapy to prevent convulsions and the timely delivery of pregnancy. Through the above introduction of the diagnostic criteria for HELLP syndrome, we also recognized that the current diagnostic and classification criteria for HELLP syndrome do not actually reflect the underlying pathogenesis of patients and the severity of the disease well, so the precise treatment of such patients cannot be conducted.

    In clinical work, when hypertension, microangiopathic hemolytic anemia (MAHA), thrombocytopenia and other manifestations occur in the third trimester of pregnancy, most obstetricians will directly diagnose HELLP syndrome, and the underlying pathogenesis of HELLP syndrome is not understood deeply enough, its treatment is very singular. It is true that early delivery can ensure maternal safety, but for patients with HELLP syndrome that occurs at less than 24–26 weeks of gestation, fetal loss occurs as a result of the termination of pregnancy to ensure maternal safety. It is worth exploring that after the termination of pregnancy, if a patient's condition is not alleviated as predicted and other clinical manifestations such as renal failure occur, the diagnosis of HELLP syndrome should be evaluated and the occurrence of pregnancy-associated thrombotic microangiopathy (TMA), such as postpartum hemolytic-uremic syndrome (PHUS), should be differentiated. In 2016, Tsai HM11 provided a thought-provoking case report of a patient who was diagnosed with SPE during the first pregnancy, HELLP syndrome during the second pregnancy, and PHUS during the third pregnancy due to postpartum renal failure, which was diagnosed by complement testing; this patient achieved good efficacy with anti-complement therapy. This forced us to examine the current overall treatment strategy for HELLP syndrome and initiate a re-exploration of its potential pathogenesis: is active prenatal termination of pregnancy the only treatment option for patients with HELLP syndrome? Should the underlying pathogenesis of “atypical” HELLP syndrome with very early onset or the basis of non-preeclampsia manifestations be more actively explored? Should the existing diagnostic criteria based on clinical manifestations be broken to break the constraints of the treatment principles, and should the disease be reclassified according to its pathogenesis to guide clinical treatment?

    3 Exploring new options for the treatment of atypical HELLP syndrome based on the pathogenesis

    Since there is an overlap between the current diagnostic criteria for partial HELLP syndrome and SPE, and clinical manifestations such as MAHA and thrombocytopenia are highly similar to PHUS, in recent years, it has been proposed that HELLP syndrome and PHUS as well as SPE are all included in pregnancy-related TMAs.12

    At present, many studies have confirmed that 50% of patients with PHUS have gene mutations of complement Factor H (CFH), the alternative pathway inhibitor of the complement system, which in turn leads to the inactivation of CFH function, as well as an abnormal activation of the complement system through the alternative pathway, resulting in hypertension, thrombocytopenia, MAHA and acute kidney injury (AKI).13,14 An increasing number of studies have suggested that HELLP syndrome, which is rare in clinical practice (incidence of approximately 0.2%), may have a pathogenesis that is more consistent with that of PHUS than that of SPE: aberrant activation of the complement system plays a more important role in HELLP syndrome and PHUS. Through gene sequencing of patients who were clinically diagnosed with HELLP syndrome, it was found that approximately 30–40% of the patients had mutations in rare complement system-related genes, similar to those in PHUS patients, and these mutations occur at a very low rate (<10%) in patients with SPE.15–18 The use of the complement system activation product C5a antagonist eculizumab can significantly improve the prognosis of patients with PHUS. Given the similarity in pathogenesis between HELLP syndrome and PHUS, is this treatment for PHUS also suitable for HELLP syndrome? In 2013, Burwick RM19 first reported a successful case of HELLP syndrome treated with eculizumab, which prolonged the pregnancy of a patient with HELLP syndrome diagnosed at 26 weeks by 16 days, thus greatly improving the neonatal prognosis and leading to the relevant clinical exploration of eculizumab in the treatment of HELLP syndrome. These successful cases suggest that for HELLP syndrome with a clinical onset earlier than 30 weeks, in addition to actively delivery according to the diagnosis and treatment norms of SPE, the potential causes of such HELLP syndrome cases should be analyzed from the perspective of pathogenesis, and various treatment options should be explored to improve the overall prognosis of the mother and child.

    4 Clinical differential diagnosis of “atypical” HELLP syndrome

    When pregnant women develop MAHA and thrombocytopenia, obstetricians will first consider SPE or HELLP syndrome, which are more common in clinical practice, and then consider other rare pregnancy-related TMAs, such as PHUS (incidence of approximately 1/25,00012). This is also in line with normal diagnostic ideas, but attention should be given to the differential diagnosis of other diseases when patients present with HELLP syndrome and have atypical clinical manifestations. Among the many non-pregnancy-induced idiopathic diseases that can lead to severe thrombocytopenia as well as MAHA, some first occur during pregnancy, and some have similar clinical manifestations to HELLP syndrome. These diseases mainly include systemic lupus erythematosus, thrombotic thrombocytopenic purpura (TTP), PHUS and antiphospholipid syndrome (APS). When the diagnosis of HELLP syndrome is questionable, the following clinical parameters can contribute to differential diagnosis: the degree of thrombocytopenia, the severity of neurological symptoms, the severity of AKI, the rate of postpartum recovery, the degree of abnormal liver function, whether the disease occurs before 30 weeks of gestation and whether it is relieved spontaneously after delivery.

    4.1 HELLP syndrome

    Most cases of HELLP syndrome occur after 34 weeks. In the cohort reported by the University of Oklahoma Medical Center,20 838 patients were diagnosed with preeclampsia, HELLP syndrome, or eclampsia, with 1 (0.1%) diagnosed at 10–19 weeks, 9 (1.1%) diagnosed before 25 weeks, and 46 (5.6%) diagnosed before 30 weeks, suggesting that the incidence of HELLP syndrome is very low before 30 weeks of gestation. Attention should be given to identify other possible diagnoses in addition to HELLP syndrome when symptoms occur before 30 weeks of pregnancy. In some cases, which are mostly reported in the form of case reports, HELLP syndrome may occur before 20 weeks of gestation due to fetal factors, often suggesting chromosomal abnormalities of the fetus, such as trisomy 13 and trisomy 18.21–23 Unlike PHUS, although HELLP syndrome can lead to AKI, injuries usually result from pronephric factors and usually does not lead to severe AKI.24 Therefore, severe AKI usually suggests that other etiologies should be investigated.

    4.2 TTP

    The pathogenesis of TTP is a decrease in ADAMTS 13 activity (<10%) due to genetic or acquired (the presence of functional inhibitory antibodies to ADAMTS 13) factors, so laboratory testing for ADAMTS 13 activity is required to confirm its diagnosis.25,26 The clinical manifestations of both hereditary and acquired TTP are highly similar to those of HELLP syndrome. Although the incidence of TTP during pregnancy is very low, obstetricians should pay attention to the differential diagnosis of TTP because it may lead to maternal death if left untreated.

    Patients with hereditary TTP often have severe adverse pregnancy outcomes. Of the 61 pregnancies in 35 patients with hereditary TTP reported by Kasht R et al.,27 34 (97%) had severe pregnancy complications, and two died during pregnancy. In view of this, if a woman has experienced a successful pregnancy and childbirth, the possibility of genetic TTP is ultimately not considered. Acute exacerbations of hereditary TTP often occur relatively early in pregnancy, with most occurring earlier than 30 weeks of gestation. In populations, the incidence of acquired autoimmune TTP is approximately 2–3 per million population/year, while the occurrence of hereditary TTP is even lower.28 However, since many patients with hereditary TTP have their initial TTP symptoms during their first pregnancy, the relative frequency of hereditary TTP compared to acquired TTP increases remarkably during pregnancy. At the French Thrombotic Microangiopathy Research Center, there were 32 women diagnosed with TTP during pregnancy, and 10 (31%) had hereditary TTP.29 Therefore, when TTP is diagnosed during pregnancy, both hereditary and acquired TTP should be considered.

    The most important laboratory value for distinguishing PE/HELLP from TTP is the platelet count. Approximately 5% of patients with HELLP syndrome have platelets <60 ​× ​109/L and 1% have platelets <30 ​× ​109/L, while patients with acquired TTP have lower platelet counts, and approximately 2% of patients with acquired TTP have platelet counts >30 ​× ​109/L.20 Although patients with hereditary TTP usually have worse clinical outcomes, their platelet levels are generally higher than those of patients with acquired TTP. The treatment of TTP is mainly to assume an acquired etiology and start plasma exchange or corticosteroid therapy. It should be pointed out that TTP and HELLP syndrome sometimes cannot be distinguished in time in clinical work, and plasma exchange therapy should also be initiated as early as possible to ensure maternal safety.

    4.3 PHUS

    As mentioned above, PHUS is associated with gene mutations that cause increased complement activation by the alternative pathway. PUHS is usually induced by pregnancy and occurs mostly in the postpartum period. Compared with patients with TTP, patients with PHUS usually have relatively mild thrombocytopenia and MAHA but develop severe AKI, which is the most important clinical manifestation that can distinguish PHUS from TTP and HELLP syndrome. Physicians should consider PHUS in women who deliver because of presumed PE/HELLP syndrome with renal injury that does not resolve in the first 48–72h postpartum, and plasma exchange or eculizumab should be initiated as early as possible.13,14

    4.4 APS

    The diagnosis of APS relies on persistent high titers of antiphospholipid antibodies (aPLs), mainly including lupus anticoagulants, anticardiolipin IgG/IgM antibodies, and anti-β2 glycoprotein I IgG/IgM antibodies, and obstetric antiphospholipid syndrome (OAPS) is characterized by adverse pregnancy outcomes. Previous studies have shown that patients with APS are at high risk of developing HELLP syndrome during pregnancy, which usually occurs before 30 weeks of gestation. An earlier study by Le TTD et al.30 found that 44% of APS patients developed HELLP syndrome before 28 gestational weeks. A recent multicenter case–control study31 showed that positive aPLs are an important indicator of poor pregnancy prognosis in patients with HELLP syndrome, thus suggesting that patients with HELLP syndrome occurring before 30 weeks of gestation should have an aPL examination to exclude the possibility of APS and avoid delaying the initiation of anticoagulant therapy.

    In addition to the diseases listed above, acute fatty liver of pregnancy (AFLP) is also a possible potential disease leading to MAHA and thrombocytopenia. Physicians should pay attention to making a differential diagnosis. Comparison of typical clinical features and specific management of disorders with MAHA and thrombocytopenia during pregnancy are shown in Table 1.

    View this table:
    Table 1

    Comparison of typical clinical features and specific management of disorders with microangiopathic hemolytic anemia and thrombocytopenia during pregnancy.

    In summary, it is not difficult to make a diagnosis of HELLP syndrome in clinical work; however, when HELLP syndrome occurs without preeclampsia manifestations or in early stage of gestation, physicians should pay attention to the differential diagnosis of a variety of diseases that can lead to thrombocytopenia and MAHA. A multidisciplinary team including maternal-fetal medicine specialists, nephrologists, hematologists, and immunologists should be established, and appropriate treatment should be provided according to the underlying pathogenesis of atypical HELLP syndrome to improve maternal and fetal outcomes.

    Funding

    This work was supported by National Natural Science Foundation of China (No. 81601303) and (No. 82071668).

    Conflict of interest

    All authors declare that there is no conflict of interest.

    References

    1. ↵
      1. Pritchard J.A.,
      2. Weisman R.,
      3. Ratnoff O.D., et al.
      Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med 1954;250(3):89–98. doi:10.1056/NEJM195401212500301
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      1. Weinstein L.
      Syndrome of hemolysis, elevated liver enzymes, and low platelet count：A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142(2):159–167. doi:10.1016/s0002-9378(16)32330-4
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      1. Weinstein L.
      It has been a great ride: the history of HELLP syndrome. Am J Obstet Gynecol 2005;193(3 Pt 1):860–863. doi:10.1016/j.ajog.2005.06.058
      OpenUrlCrossRefPubMed
    4. ↵
      1. Ditisheim A.,
      2. Sibai B.M.
      Diagnosis and management of HELLP syndrome complicated by liver hematoma. Clin Obstet Gynecol 2017;60:190.
      OpenUrlPubMed
    5. ↵
      1. Martin J.N. Jr.,
      2. Blake P.G.,
      3. Perry K.G. Jr., et al.
      The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991;164:1500–1509.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      1. Sibai B.M.
      Diagnosis controversies and management of the syndrome of hemolysis elevated liver enzymes and low platelet count. Obstet Gynecol 2004;103(5Pt 1):981–991.
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      Pregnant hypertension disease group of obstetrics and gynecology college in Chinese Medical Association. Guideline for hypertensive disorders of pregnancy (2020). Chin J Obstet Gynecol 2020;55(4):227–238.
      OpenUrl
    8. ↵
      1. Phipps E.A.,
      2. Thadhani R.,
      3. Benzing T., et al.
      Preeclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019;15(5):275–289. doi:10.1038/s41581-019-0119-6
      OpenUrlCrossRefPubMed
    9. ↵
      1. Vinnars M.T.,
      2. Wijnaendts L.,
      3. Westgren M., et al.
      Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008;51(5):1295–1299. doi:10.1161/HYPERTENSIONAHA.107.104844
      OpenUrlCrossRef
    10. ↵
      1. Sep S.,
      2. Verbeek J.,
      3. Koek G., et al.
      Clinical differences between early-onset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum. Am J Obstet Gynecol 2010;202:271.e1. doi:10.1016/j.ajog.2009.10.874. 271.e5
      OpenUrlCrossRefPubMed
    11. ↵
      1. Tsai H.M.,
      2. Kuo E.
      From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome. Obstet Gynecol 2016;127(5):907–910. doi:10.1097/AOG.0000000000001340. 127(3):657
      OpenUrlCrossRef
    12. ↵
      1. George J.N.,
      2. Nester C.M.
      Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371(19):1847–1848. doi:10.1056/NEJMc1410951
      OpenUrlCrossRefPubMed
    13. ↵
      1. Noris M.,
      2. Remuzzi G.
      Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361(17):1676–1687. doi:10.1056/NEJMra0902814
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      1. Noris M.,
      2. Remuzzi G.
      Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. Nat Clin Pract Nephrol 2005;1(1):2–3. doi:10.1038/ncpneph0018
      OpenUrlCrossRefPubMed
    15. ↵
      1. Fakhouri F.,
      2. Jablonski M.,
      3. Lepercq J., et al.
      Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008;112(12):4542–4545. doi:10.1182/blood-2008-03-144691
      OpenUrlAbstract/FREE Full Text
    16. ↵
      1. Vaught A.J.,
      2. Braunstein E.M.,
      3. Jasem J., et al.
      Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018;3(6):e99128. doi:10.1172/jci.insight.99128
      OpenUrlCrossRef
    17. ↵
      1. Delvaeye M.,
      2. Noris M.,
      3. De Vriese A., et al.
      Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009;361(4):345–357.
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      1. Burwick R.M.,
      2. Feinberg B.B.
      Complement activation and regulation in preeclampsia and HELLP syndrome. Am J Obstet Gynecol 2022;226(2S):S1059–S1070. doi:10.1016/j. ajog.2 020.09.038
      OpenUrlCrossRef
    19. ↵
      1. Burwick R.M.,
      2. Feinberg B.B.
      Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013;34(2):201–203. doi:10.1016/j.placenta.2012.11.014
      OpenUrlCrossRefPubMed
    20. ↵
      1. Reese J.A.,
      2. Peck J.D.,
      3. Deschamps D.R., et al.
      Platelet counts during pregnancy. N Engl J Med 2018;379(1):32–43. doi:10.1056/NEJMoa1802897
      OpenUrlCrossRef
    21. ↵
      1. Spartz E.,
      2. Sarwar R.,
      3. Jacobs K., et al.
      Elevated liver enzymes secondary to early second trimester HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count). Am J Gastroenterol 2021;116(9):1963–1964. doi:10.14309/ajg.0000000000001288
      OpenUrlCrossRef
    22. ↵
      1. Myer E.,
      2. Hill J.
      First trimester hemolysis, elevated liver enzymes, low platelets syndrome in a surrogate pregnancy. AJP Rep 2015;5(2):e212–e214. doi:10.1055/s-0035-1563389
      OpenUrlCrossRef
    23. ↵
      1. Bornstein E.,
      2. Barnhard Y.,
      3. Atkin R., et al.
      HELLP syndrome: a rare, early presentation at 17 weeks of gestation. Obstet Gynecol 2007;110(2 II):525–527. doi:10.1097/01.AOG.0000268512.26170
      OpenUrlCrossRefPubMed
    24. ↵
      1. Conti-Ramsden F.I.,
      2. Nathan H.L.,
      3. De Greeff A., et al.
      Pregnancy-related acute kidney injury in preeclampsia: risk factors and renal outcomes. Hypertension 2019;74:1144–1151. doi:10.1161/HYPERTENSIONAHA.119.13089
      OpenUrlCrossRefPubMed
    25. ↵
      1. Wade A.N.,
      2. Panchmatia R.,
      3. Calderon P.
      Hemolysis, elevated liver enzymes, and low platelet count syndrome with severe thrombocytopenia and severe ADAMTS13 activity deficiency. Obstet Gynecol 2021;137(5):873–876. doi:10.1097/AOG.0000000000004345
      OpenUrlCrossRef
    26. ↵
      1. Botero P.J.,
      2. Reese J.A.,
      3. George J.N., et al.
      Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: a guide for the consulting hematologist. Am J Hematol 2021;96(12):1655–1665. doi:10.1002/ajh.26328
      OpenUrlCrossRef
    27. ↵
      1. Kasht R.,
      2. Borogovac A.,
      3. George J.N.
      Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura. Am J Hematol 2020;95:E316–E318. doi:10.1002/ajh.25964
      OpenUrlCrossRef
    28. ↵
      1. Page E.E.,
      2. Little D.J.,
      3. Vesely S.K., et al.
      Quinine-induced thrombotic microangiopathy: a report of 19 patients. Am J Kidney Dis 2017;70:686–695. doi:10.1053/j.ajkd.2017.05.023
      OpenUrlCrossRef
    29. ↵
      1. Moatti-Cohen M.,
      2. Garrec C.,
      3. Wolf M., et al.
      French reference center for thrombotic microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012;119(24):5888–5897. doi:10.1182/blood-2012-02-408914
      OpenUrlAbstract/FREE Full Text
    30. ↵
      1. Le T.T.D.
      The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women[J]. Ann Rheum Dis 2005;64(2):273–278. doi:10.1136/ard.2003.019000
      OpenUrlAbstract/FREE Full Text
    31. ↵
      1. Pécourt M.,
      2. Yelnik C.,
      3. Ghesquiere L., et al.
      Is the presence of antiphospholipid antibodies a poor prognostic factor for patients with hemolysis, elevated liver enzymes, and low platelet count syndrome?. Am J Obstet Gynecol 2021;225(4):doi:10.1016/j.ajog.2021.03.039. 432.e1-432432.e7
      OpenUrlCrossRef